CellaVision AB: CellaVision invites to a telephone and audio webcast on September 17, at 11:00 CET to present the signing of an agreement to acquire t
The information was submitted to the public on September 16, 2019 at 18:45
CellaVision AB (publ) announced on September 16, 2019, at 18:30 CET that
the company has signed an agreement to acquire the French company RAL
Diagnostics (RAL). The full-length press release is available at
In connection with the release analysts, investors and the media are hereby
invited to a telephone conference and audio webcast at 11:00 CET where
Zlatko Rihter, President & CEO, will present the planned acquisition.
The presentation will be in English via a conference call or audio webcast:
Phone number for the conference:
No pre-registration is required. Please dial in 5-10 minutes prior to the
scheduled start time to facilitate a timely start.
CellaVision is an innovative, global medical technology company that
develops and sells its own leading systems for routine analysis of blood
and other body fluids in health care services. The products replace manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge
expertise in image analysis, artificial intelligence and automated
microscopy. Sales are via global partners with support from the parent
company in Lund and by the companys 17 local market support organizations
covering more than 30 countries. In 2018, sales were SEK 365 million and
the companys growth target is 15% per year over an economic cycle.
CellaVisions registered office is in Lund, Sweden. The share is listed on
the Nasdaq Stockholm, Mid Cap list.
Read more at www.cellavision.com